A study to evaluate the effectiveness and safety of Sofosbuvir/velpatasvir/voxilaprevir in a prospective registry of coinfected patients treated with direct active antivirals
Latest Information Update: 29 Mar 2022
At a glance
- Drugs Sofosbuvir/velpatasvir/voxilaprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
Most Recent Events
- 29 Mar 2022 New trial record
- 16 Feb 2022 Results presented at the 29th Conference on Retroviruses and Opportunistic Infections